Bayless Integrated Healthcare

baylesshealthcare.com

Bayless Integrated Healthcare strives to be your primary care partner, where “care” for your whole family is our passion. We focus on your entire health and wellness and have doctors and healthcare providers ready and trained to work with all ages. Together, we are dedicated to support your family’s physical, emotional, behavioral, and social health needs. Founded in 1982, Bayless is a comprehensive healthcare provider that takes a whole body multi-disciplinary approach to medical treatment, delivering better results and an improved patient experience. Based in Phoenix, Arizona, Bayless serves all ages and socio-economic classes.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights, PHARMACY MARKET

ACCORD HEALTHCARE EXPANDS OFFERINGS WITH GENERIC RELAPSING MS DRUG

Accord Healthcare | March 14, 2023

news image

On March 13, 2023, Accord Healthcare informed that it has expanded its portfolio with Teriflunomide, a film-coated tablet equivalent to Sanofi Genzyme's Aubagio. The drug treats relapsing forms of MS in adults, including clinically-isolated syndrome and active secondary progressive disease. The company offers Teriflunomide in 14 mg and 7 mg tablets, now available for shipping. Teriflunomide has been granted FDA approval as an immunomodulatory agent for patients aged 18 and a...

Read More

Business Insights

XERIS BIOPHARMA ENTERS INTO AGREEMENT FOR $30 MILLION PRIVATE PLACEMENT

Xeris Biopharma Holdings | January 04, 2022

news image

Xeris Biopharma Holdings, Inc. a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that on January 2, 2022, it entered into a securities purchase agreement in connection with a private placement with an affiliate of Armistice Capital, LLC for aggregate gross proceeds of approximately $30.0 million. The Private Placement is expected to close on or around January 3, 2022.
Read More

IN THE WORLD OF BIG PHARMA, AN ITALIAN ORAL SPRAY SURVIVES

Dr ZinX | July 10, 2020

news image

Yonah S. Tehrani, MD on the potential benefit of the Dr ZinX Zinc + Hinokitiol combination: "The antiviral effects and benefits of Zinc and Hinokitiol may have a tremendous impact on affected individuals and health care systems worldwide." Zinc is a mineral of critical importance to the proper functioning of the immune system in all age groups. Zinc deficiency may result in low resistance to viruses and bacteria. Studies dating back to 1974 have shown that zinc supplemen...

Read More

Business Insights

SANOFI GLOBAL HEALTH LAUNCHES NONPROFIT IMPACT® BRAND FOR 30 MEDICINES IN LOW-INCOME COUNTRIES

Sanofi | July 05, 2022

news image

Sanofi Global Health announces the launch of Impact®, a new brand of standard of care medicines produced by Sanofi dedicated for nonprofit distribution to at-risk populations in the world’s most impoverished countries. The Impact® brand, which includes insulin, glibenclamide and oxaliplatin amonst others, will enable the secure distribution of 30 Sanofi medicines in 40 lower-income countries. Considered essential by the World Health Organization, the medicines cover ...

Read More
news image

Business Insights, PHARMACY MARKET

ACCORD HEALTHCARE EXPANDS OFFERINGS WITH GENERIC RELAPSING MS DRUG

Accord Healthcare | March 14, 2023

On March 13, 2023, Accord Healthcare informed that it has expanded its portfolio with Teriflunomide, a film-coated tablet equivalent to Sanofi Genzyme's Aubagio. The drug treats relapsing forms of MS in adults, including clinically-isolated syndrome and active secondary progressive disease. The company offers Teriflunomide in 14 mg and 7 mg tablets, now available for shipping. Teriflunomide has been granted FDA approval as an immunomodulatory agent for patients aged 18 and a...

Read More
news image

Business Insights

XERIS BIOPHARMA ENTERS INTO AGREEMENT FOR $30 MILLION PRIVATE PLACEMENT

Xeris Biopharma Holdings | January 04, 2022

Xeris Biopharma Holdings, Inc. a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that on January 2, 2022, it entered into a securities purchase agreement in connection with a private placement with an affiliate of Armistice Capital, LLC for aggregate gross proceeds of approximately $30.0 million. The Private Placement is expected to close on or around January 3, 2022.
Read More

news image

IN THE WORLD OF BIG PHARMA, AN ITALIAN ORAL SPRAY SURVIVES

Dr ZinX | July 10, 2020

Yonah S. Tehrani, MD on the potential benefit of the Dr ZinX Zinc + Hinokitiol combination: "The antiviral effects and benefits of Zinc and Hinokitiol may have a tremendous impact on affected individuals and health care systems worldwide." Zinc is a mineral of critical importance to the proper functioning of the immune system in all age groups. Zinc deficiency may result in low resistance to viruses and bacteria. Studies dating back to 1974 have shown that zinc supplemen...

Read More
news image

Business Insights

SANOFI GLOBAL HEALTH LAUNCHES NONPROFIT IMPACT® BRAND FOR 30 MEDICINES IN LOW-INCOME COUNTRIES

Sanofi | July 05, 2022

Sanofi Global Health announces the launch of Impact®, a new brand of standard of care medicines produced by Sanofi dedicated for nonprofit distribution to at-risk populations in the world’s most impoverished countries. The Impact® brand, which includes insulin, glibenclamide and oxaliplatin amonst others, will enable the secure distribution of 30 Sanofi medicines in 40 lower-income countries. Considered essential by the World Health Organization, the medicines cover ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us